GlassScriptPhysician profile
Edward L Kramer
NPI 1992749329
$5,726.29
in general payments reported to CMS, 2019-2025
30 companies · $22.29 in 2025
The $22.29 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $216 · 2020: $136 · 2021: $989 · 2022: $1,485 · 2023: $1,278 · 2024: $1,600 · 2025: $22.29.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,900.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,900.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $619.05 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $543.94 | 2021-2024 | |
| Amneal Pharmaceuticals LLC | $509.77 | 2019-2024 | Rytary, Lyvispah, Ongentys 50mg Capsules 30 |
| Pfizer INC. | $371.34 | 2023-2024 | |
| Amgen INC. | $330.62 | 2019-2023 | Aimovig |
| Kyowa Kirin, INC. | $326.07 | 2021-2024 | Nourianz |
| Alexion Pharmaceuticals, INC. | $313.74 | 2019-2024 | Ultomiris |
| Biogen, INC. | $303.62 | 2019-2024 | Spinraza, Qalsody, Tysabri |
| Lilly USA, LLC | $276.07 | 2020-2024 | Amyvid, Emgality, Kisunla |
| Emd Serono, INC. | $258.55 | 2023-2024 | Mavenclad |
| Sk Life Science, INC. | $255.12 | 2020-2024 | |
| Teva Pharmaceuticals USA, INC. | $254.88 | 2019-2024 | Austedo Xr, Austedo, Ajovy |
| Ucb, INC. | $217.50 | 2021-2024 | Zilbrysq, Briviact |
| Lundbeck LLC | $191.29 | 2021-2024 | Vyepti |
| Argenx US, INC. | $140.16 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $124.47 | 2021 | |
| Genzyme Corporation | $114.35 | 2019-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $108.47 | 2022 | |
| Allergan, INC. | $105.02 | 2021-2022 | |
| Tanabe Pharma America, INC. | $90.21 | 2022-2024 | |
| Eisai INC. | $54.73 | 2021-2022 | |
| Neurelis, INC. | $50.43 | 2021-2024 | Valtoco |
| Avanir Pharmaceuticals, INC. | $37.82 | 2019 | |
| Neurocrine Biosciences, INC. | $36.78 | 2024 | Ingrezza |
| Banner Life Sciences, LLC | $19.55 | 2023 | |
| Supernus Pharmaceuticals, INC. | $17.96 | 2021 | |
| Ge Healthcare | $16.18 | 2022 | |
| Tg Therapeutics, INC. | $16.15 | 2023 | |
| Catalyst Pharmaceuticals, INC. | $11.51 | 2021 | |
| Acorda Therapeutics, INC | $10.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Kramer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.